BTK and mantle cell lymphoma: Acalabrutinib is a selective Bruton's tyrosine kinase (BTK) inhibitor.154 Its combination with bendamustine, an alkylating agent, and rituximab, an anti-CD20 monoclonal antibody, was approved in January 2025 for the treatment of previously untreated mantle cell lymphoma (MCL) in patients ineligible for autologous stem cell transplantation.155 This regimen leverages the synergistic effects of BTK inhibition and chemoimmunotherapy, resulting in improved progression-free survival and manageable toxicity profiles156 (Table 1).